A Splice of Life Science Marketing

Scientist buyers use falsification logic -- one weak claim destroys your whole case -- so claim selection and buyer presence beat validation volume every time.ShownotesYour claims list passed legal, survived MS3, and still didn't land. The problem wasn't your evidence -- it was which claim was leading and whether your buyer was still in the room when you chose it.This episode is for life science marketers, product managers, and commercial leaders building claims hierarchies for scientist buyers.Jasmine and Matt unpack why scientist buyers apply falsification logic to commercial claims -- meaning one weak point invalidates everything before it -- while most commercial teams build on accumulation logic. They explore how organisational gravity edits the buyer out of decisions before anything reaches the field, and how a synthetic customer built from real voice-of-customer data can keep buyer presence active throughout the review process.Key idea: Your buyer has already left the room before the claims list is written, edited out by organisational gravity -- and a synthetic customer keeps them present throughout.Why accumulation logic and falsification logic produce opposite commercial outcomes for the same claims listHow a single weak claim destroys scientist buyer confidence regardless of how many strong ones precede itWhy claim selection is a commercial judgement, not a validation problemHow organisational gravity pulls messaging toward what is safest rather than what the buyer needsWhat a synthetic customer is, what it is built from, and what it cannot replaceHow to test whether your buyer has already left the room before your next review cycleKeywords: life science marketing, scientist buyers, falsification logic, claims hierarchy, MS3 review, synthetic customer, organisational gravity, product marketing, voice of customer, commercial claims, accumulation logic, buyer presenceIf this episode changed how you think about your next review cycle, subscribe to A Splice of Life Science Marketing and visit strivenn.com for the full blog posts referenced in this episode. We answer every message.

AI agents are shortlisting life science suppliers before humans get involved - brands invisible to AI are losing demand they cannot measure.Shownotes:Your next buyer might never visit your website. AI agents are already shortlisting suppliers, summarising product pages, and filtering out brands with poor machine-readable content - before any human in procurement gets involved.For life science marketers and commercial leaders who want to understand what the shift to AI-mediated discovery actually means for their brand right now.Matt Wilkinson's blog post "Your Next Buyer Might Be an Algorithm. Is Your Brand Ready?" sparked a sharp debate between Matt and Jasmine Gruia-Gray. The conversation moves from the Meta acquisition of Moltbook and OpenAI's hire of the OpenClaw engineer through share of model measurement, Generative Engine Optimisation, prompt injection risk, and the first mover argument - testing where the evidence is solid and where the hype needs qualifying.Key idea: AI agents are increasingly making shortlisting decisions before humans get involved - life science brands with no AI visibility strategy are losing demand they cannot even measure.What you will learn:What the Meta acquisition of Moltbook and OpenAI's OpenClaw hire signal about the commercial infrastructure being built for AI agentsWhat "share of model" means as a concept - and the honest measurement constraints that come with itHow Generative Engine Optimisation differs from SEO and which version is deliverable for a small marketing teamHow prompt injection works, what Microsoft Defender found in 60 days of monitoring, and where the real competitive risk sitsWhy citation compression means AI visibility has no page two - and what Strivenn's SLAS 2026 data reveals about where life science companies currently standThe first mover argument examined critically - including the risk-adjusted case for acting now even with infrastructure still years from maturityChapters:[00:42] Introduction and framing[02:45] Share of model - what it is and the measurement challenge[06:17] Attribution constraints and the agent monitoring opportunity[08:02] GEO versus SEO - overlap, divergence, and what is deliverable[10:04] Cross-functional dependencies and schema implementation reality[12:44] Prompt injection risk - competitive threat or reputational hazard?[15:35] Building authority versus near-term competitive exposure[18:32] First mover advantage - the honest version of the investment case[20:26] Citation compression and the cost of waiting[22:48] Practical next stepsKeywords: AI discoverability, life science marketing, share of model, generative engine optimisation, GEO, prompt injection, AI agents, B2AI, citation compression, agentic AI, AI recommendation visibility, life science commercial strategyIf this episode shifted how you think about AI visibility for your brand, subscribe to A Splice of Life Science Marketing for new episodes every fortnight. Read the full blog post and explore the AI Discoverability Hub for primary research, frameworks, and a practical audit at strivenn.com.

Persona AI keeps the customer present through organisational gravity - the internal approval process that dilutes buyer insight before launch.You did the interviews. You built the personas. The campaign went to market and the open rates collapsed. The research was not the problem - the buyer left the room somewhere between the first draft and the final approval.This episode is for life science marketers who have watched good insight get softened by legal, reshaped by product, and diluted by a VP's instinct - and are looking for a structural fix that keeps the customer present throughout the entire commercial process.Matt Wilkinson and Jasmine debate the organisational gravity problem: the predictable force that pulls marketing content away from buyer language and toward internal consensus. Matt argues that grounded Persona AI - a synthetic customer built from real voice-of-customer data - changes the evidence dynamic at every stage of review, not just at briefing. Jasmine pressure-tests whether visibility alone is enough to change organisational behaviour, and where the solution has genuine limits.The key idea: AI can not only help you create better personas, it can help you keep those insights with you as you traverse the internal politics of approval - the process Matt calls organisational gravity.What you will learn:Why organisational gravity turns customer documents into consensus documents - and what to do about itHow a synthetic customer creates evidence at every stage of review, not just at briefingThe difference between making misalignment visible and having the infrastructure to act on itWhat the minimum viable input set looks like for a grounded Persona AI - and why it is lower than most teams assumeHow to use Persona AI as a supplement to real buyer conversations, not a substitute for themWhy a shared synthetic customer surfaces sales and marketing tension rather than papering over itKeywords: persona AI, life science marketing, organisational gravity, synthetic customer, voice of customer, B2B content strategy, marketing and sales alignment, buyer personas, life science commercialisation, content approval process, customer centricity, AI in marketingIf this episode resonated, subscribe and leave a review - it helps more life science marketers find the conversation. Read the original blog post that sparked this debate: Walking in the Customer's Shoes. Explore Persona AI and Strivenn's full thinking at strivenn.com.

Beta programs designed for validation rather than stress testing create launch liabilities that surface as field quality crises three to six months post-launch.Your beta sites completed the study. A KOL sent a positive note. Nobody filed a reproducibility complaint. You called it a validation and moved to launch. Then your field application scientist hit an edge case none of your beta sites ever flagged.This episode is for product managers and commercial leaders in RUO life sciences who run beta programs and believe positive signal means the product is ready.Matt and Jasmine debate a structured framework for redesigning beta programs around diagnostic rigour rather than confidence generation. The conversation covers brief design, structured failure mode testing, negative finding attribution, and the political reality of presenting a rigorous program to a launch team under schedule pressure.The core argument: in RUO life sciences, a comfort-driven beta does not miss signal. It builds a launch liability.What you will learn:Why a brief with a three-to-one ratio of strengths to stress tests is a confidence document, not a diagnostic toolHow internal validation and beta serve fundamentally different evidentiary functionsWhat structured failure mode testing looks like in practice and why it is not a remediation of R&D gapsHow to reframe a negative finding as a claim boundary rather than a launch delayWhy the default attribution instinct toward operator error is asymmetrically riskyHow to set attribution standards before the program runs rather than under debrief pressureKeywords: beta program design, RUO life sciences, product launch, life science marketing, product management, KOL management, field quality, claims development, beta brief, stress testing, launch readiness, life science commercialisationSubscribe to A Splice of Life Science Marketing for weekly conversations on strategy, commercialisation, and the decisions that shape life science brands. Visit strivenn.com to learn more.

Life science PMs can reclaim strategic time using the DRAG framework -- but only if those hours go back into customer discovery, not more admin.You reformatted a competitive comparison slide for sales. It took 40 minutes. They looked at it for 90 seconds. That gap -- between feeling productive and being strategic -- is exactly what this episode is about.Jasmine Gruia-Gray joins Matt Wilkinson to interrogate the DRAG framework (Drafting, Research, Analysis, Grunt work) -- an AI delegation system designed for life science product managers who are drowning in admin they never chose to take on.Who this is for: Life science product managers, commercial leads, and marketers in biotech and pharma who suspect their calendar is full but their strategic output is thin.Matt and Jasmine cover the completion bias trap that keeps PMs stuck in low-value work, the honest math behind the 15-to-20-hour time recovery claim, and the real risk of AI delegation -- not the obvious one you expect, but the subtler cognitive offloading problem that could quietly blunt your anomaly detection over time.The key idea: The DRAG framework is an AI delegation system, not a time-saving shortcut -- the reclaimed hours only matter if you spend them on customer discovery.What you will learn:What completion bias is and why it explains most of the PM admin problem -- backed by HBR data on how CEOs and PMs waste structured work timeHow the AIM protocol (Actor, Input, Mission) solves the blank page problem for AI-assisted drafting in technically specialised life science contextsWhy the 15-to-20-hour recovery figure is a ceiling you build toward, not a day-one promise -- and what week one actually looks likeThe difference between AI synthesis and human interpretation, and why conflating the two is where strategic decay beginsHow to use DRAG to change stakeholder expectations through performance, not by waiting for organisational redesignThe one test that tells you whether your AI delegation has crossed into cognitive surrender: if you spend more time reviewing AI output than talking to customers, you have gone too farKeywords: life science product management, AI delegation, DRAG framework, completion bias, AI productivity, life science marketing, biotech product manager, AI tools life sciences, strategic time management, cognitive offloading, product management framework, AI workflowIf this conversation challenged how you think about where your attention goes, subscribe and share it with a PM who is still reformatting slides at 5pm. Visit strivenn.com to explore AI-enabled commercial strategy for life science companies.

If your brand isn't cited by AI tools when buyers search your category, you're not losing a ranking - you're being skipped entirely before the decision is made.Open ChatGPT, Perplexity, or Google AI Mode right now and type: "Name the top three companies in [your product category]." If your brand isn't in the answer, you're not losing a click. You're not even in the race.This episode is for life science marketers and commercial leaders who want to understand - and act on - AI discoverability before their competitors do.Matt Wilkinson and Jasmine Gruia-Gray debate the six-phase AI discoverability audit: a structured, agency-free framework designed to help life science brands earn citation presence in AI-generated answers. The conversation moves fast, challenges assumptions, and gets into the practical friction points that most audit frameworks gloss over - from entity consistency and ungating strategy to proxy pages and measurement cadence.The key idea: if your brand isn't cited by AI tools when buyers search your category, you're not losing a ranking - you're being skipped entirely before the decision is made.What you will learn:Why entity consistency across platforms is the foundation of AI discoverability - and why mismatched descriptions confuse AI models at an identity levelThe real debate between fixing entity consistency first versus ungating content - and why the sequencing matters more than you thinkHow proxy pages work as a halfway house between gated content and full discoverability - and where that trade-off breaks downWhy 50 manual queries every 90 days is more achievable than it sounds - and the hidden bias problem that can corrupt your resultsHow AI models are building personalised understanding of individual users - and what that means for running clean discoverability testsWhy getting your positioning stable now matters: dual-use bots are feeding your content back into model training runs, so consistency compoundsSubscribe to A Splice of Life Science Marketing for weekly debates on AI, strategy, and commercial growth in life science. Visit strivenn.com to access the AI discoverability audit framework and the Strivenn AI Readiness Diagnostic.

Your company's scientific content is exactly what AI models want to cite - and you're hiding it behind a gate. In this episode, Matt and Jasmine unpack two uncomfortable commercial realities: why life science brands are invisible in AI search despite decades of peer-reviewed credibility, and why most soft launches are risk management exercises dressed up as market learning.This episode is for marketers, product managers, and commercial leaders in life science, diagnostics, and lab tools who need to know how AI discoverability is reshaping the citation landscape - and why the way you design a soft launch determines whether your sales team inherits signal or ambiguity.Key idea: Life science companies have a structural AI citation advantage that they are not capturing - because the content is gated, unattributed, or published in formats AI cannot parse.What you will learn:Why NIH and Science Direct dominate AI citations in health and science domains - and what that means for your content strategyThe three structural problems compounding AI invisibility: gated content, ghost writing, and channel mismatchWhy the quarterly discoverability test is deceptively simple - and why that is a feature, not a flawHow field application scientists can close the quality gap in your GEO executionWhy the soft launch is not a risk management tool - and what happens when you treat it as oneHow to define exit criteria before the soft launch begins and why that single decision determines everythingChapters:[00:42] Introduction[00:49] Jasmine sets up the GEO article - AI citation compression in life science[04:03] Who owns the AI visibility problem?[05:50] Why it is not just a marketing problem - product development and GEO[07:37] How marketing can elevate scientific content for bots and humans[09:00] Is the gated content trade-off as clear as it seems?[10:50] Execution concerns: who writes the structured summaries?[12:22] The field application scientist as a GEO teammate[13:38] Does ghost-written content hurt discoverability?[14:34] The politics of named authors in scientific organisations[16:51] Is a quarterly discoverability test enough?[18:04] How to tell which assets are driving your AI visibility[19:13] Using AI to interrogate its own pattern recognition[20:55] Matt introduces Jasmine's soft launch article[22:56] What a soft launch should actually be measuring[24:05] The political problem - product managers without organisational authority[25:30] Early adopters versus early customers - Rogers' hard line[27:21] Exit criteria and the single named decision maker[29:04] When to skip the soft launch entirely[30:24] Matt's synthesis: a soft launch is a named question, not a harbourKeywords: life science marketing, AI discoverability, GEO, generative engine optimisation, AI citation, soft launch, product launch strategy, life science commercialisation, scientific content marketing, AI search, citation compression, Rogers diffusion of innovationsSubscribe to A Splice of Life Science Marketing for weekly conversations on strategy, AI, and commercial growth in life sciences. Visit strivenn.com to learn more.

AI discoverability and product line extensions share the same root problem: misclassification kills outcomes before execution even begins.Most life science companies are optimising the wrong thing - and paying for it twice. In this episode, Matt and Jasmine expose two pressure patterns that product managers and marketers recognise immediately but rarely diagnose correctly: AI visibility that depends on brand signals most companies don't have, and line extension labels applied for political convenience rather than classification accuracy.This episode is for life science marketers and product managers navigating AI-driven discovery, stage gate processes, and the uncomfortable conversations that live upstream of both.Key idea: Whether you are building AI discoverability or launching a new product, the classification decision is the fault line - not the execution that follows from it.Why brand search volume, not content quality, is the strongest predictor of AI citationHow entity consistency across platforms unlocks AI visibility for challenger brandsWhy the line extension label is often a timeline tool rather than a classification decisionHow to apply a three-dimension framework (who, how, what) before stage gate classification locks inWhat product managers can do when the classification fight is already lost at the gateWhy continuous improvement of the process itself matters as much as the products moving through it[00:42] Introduction[01:14] AI citation: why brand search volume beats content quality[05:25] The entity consistency fix most companies haven't done[07:38] Agents, content operating systems, and the compounding content programme[09:20] Brand override and word of mouth in an AI-mediated world[10:25] The line extension trap - who pays when the label is wrong[12:43] The triad framework: who, how, and what[15:03] Making the deployment gap concrete enough to fund[17:29] What to do when leadership won't listen - yet[20:41] Is this a skills problem or a structural failure?[22:06] Continuous improvement of the process, not just the product[23:10] CloseKeywords: AI discoverability, AEO life science, entity consistency, brand search volume, line extension misclassification, stage gate, product manager, life science marketing, GEO content, AI citationSubscribe to A Splice of Life Science Marketing for weekly conversations at the intersection of commercial strategy, AI, and life science growth. Visit strivenn.com to learn more.What you will learnChapters

Most life science companies haven't checked whether AI recommends them. The ones that have are already pulling ahead.In this episode, Matt Wilkinson and Jasmine Gruia-Gray dig into the real commercial stakes of AI search visibility for life science tools and diagnostics companies - cutting through the AEO/GEO hype to ask the harder question: who in your organisation actually owns this?This episode is for: Marketing leaders, commercial directors, and CEOs at life science tools, diagnostics, and biotech companies who want to understand what AI discoverability actually means for pipeline and brand - and why it's a leadership problem, not a content one.KEY IDEA: AI discoverability is a leadership mandate, not a content strategy problem.What you will learn:Why 62% of life science exhibitors have never run the basic AI visibility test - and what that means commerciallyThe citation compression dynamic: AI surfaces roughly five brands per B2B category, and that list is hardening nowWhy absence from AI recommendations is categorically different from ranking fifth on GoogleThe structural AI citation advantage life science companies hold - and why most can't access itWhy framing this as a content project guarantees you hit a ceilingWhat the organisations that win will have in common: a named leader with cross-functional authorityKeywords: AI discoverability, life science marketing, AEO, GEO, answer engine optimisation, citation compression, AI search, B2B life science, biotech marketing, AI visibility, LLM search, AI overviewsWatch the full episode, subscribe to A Splice of Life Science Marketing, and explore Strivenn's AI readiness resources at strivenn.com.

Your competitor just ran a better demo than you — before the exhibit hall opened. Every scientist on that floor already benchmarked your product against theirs using AI search. The question isn't whether they know your specs. It's whether they trust your team enough to take the next step.This episode is for life science marketers, commercial leaders, and product managers who want to rethink what trade shows and AI adoption are actually for. Matt Wilkinson and Jasmine Gruia-Gray unpack two interconnected arguments: the conference booth has shifted from information delivery to human conviction channel, and AI adoption in commercial teams is no longer a tool question — it is a structural one. In a world where AI handles the information war, the trade show booth and your commercial team's judgment are now your only true differentiators — and both require deliberate investment to protect.Why badge scan targets are a legacy behaviour from a pre-Google conference playbookWhat "disrupting the digital" actually means for your booth strategyWhy admitting the edge of your knowledge is the most credible signal your booth can sendHow to capture the exact language your prospects use — and why it mattersWhy AI adoption in life science commercial teams compounds advantage or compounds errorWhat deliberate adoption looks like, and why organisational discipline is the missing ingredient[00:42] Introduction — SLAS 2026 and two uncomfortable arguments[03:21] The booth as human conviction channel[04:28] Why badge scans are the wrong metric[05:17] What good looks like on the trade show floor[06:31] Handling the moment your expert is unavailable[07:37] Stop trying to impress — start listening[09:26] Booths as customer advisory boards[10:54] Transition: from booth strategy to AI adoption[14:10] Is the AI adoption gap structural?[15:32] Survivorship bias and the science of making claims[16:43] Evidence from beyond life science — and what it signals[18:02] What judgment amplification looks like in practice[20:22] Deliberate adoption vs. stagnation[21:40] Organisational discipline and mandated AI guidelines[22:36] Who owns this — and what is the first real move?[23:41] The measurement problem leadership has not solved yet[25:09] AI amplifies human insight — if humans are still in the loop

Right now, an AI is deciding whether your brand exists. Not philosophically - commercially. Life science researchers are asking ChatGPT for flow cytometry recommendations, using Perplexity to compare qPCR platforms. If AI can't find, cite, and recommend you, you're invisible.Matt Wilkinson and Jasmine Gruia-Gray debate the commercial reality of generative engine optimisation for B2B life science companies. Is it brand building or performance marketing? The answer matters more than you think.What we cover:→ Why AI search traffic converts 23x better than organic (but represents <1% of volume)→ The mechanics of query fan-out and probabilistic visibility models→ Incumbent advantage vs newcomer opportunity in AI discovery→ Platform-specific biases: Grok, ChatGPT, Claude, Perplexity→ The 3-6 month GEO timeline and product confidentiality tensions→ Practical testing framework for competitive AI visibility mappingReferenced in this episode:Rand Fishkin (SparkToro) and Mike King (iPullRank) on AI search mechanicsAhrefs data on conversion rates from AI search trafficForrester research: 90% of B2B purchases use generative AIActionable takeaway: Spend an hour quarterly prompting ChatGPT and Perplexity with your category question and specific use case. Who shows up? That gap is your competitive map for AI discovery.About A Splice of Life Science Marketing:Strategic conversations for marketing leaders navigating AI adoption, commercial execution, and buyer psychology in life sciences.Connect with Matt Wilkinson:LinkedIn: https://www.linkedin.com/in/mattwilkinson/Strivenn: strivenn.comNewsletter: https://strivenn.com/subscribeConnect with Jasmine Gruia-Gray:LinkedIn: https://www.linkedin.com/in/jasmine-gruia-gray-phd/#lifescience #marketing #AI #GEO #B2Bmarketing

AI accelerates conference prep and TAM models, but capture depends on listening skills and pain point differentiation, not just data.Shownotes:Most life science teams show up to conferences with product specs and TAM models built on market size. Both fail for the same reason: they prove something exists without proving you can win.This episode is for product managers and marketers preparing for their next conference or portfolio review. Matt Wilkinson and Jasmine Gruia-Gray unpack data from the ELRIG Drug Discovery 2025 exhibitor survey and dissect why competitive revenue triangulation without capture strategy kills viable products.Preparation without presence fails at conferences, and TAM without capture strategy fails in portfolio reviews.What you will learn:Why 86% of exhibitors lack battle cards and how AI collapses the preparation gap from days to minutesThe authenticity risk when AI prep becomes a script instead of a launchpad for listeningWhy leading with TAM size gets you stumped by "why would anyone switch?" in portfolio reviewsHow pain point differentiation prevents conservative TAM analysis from killing $60 million opportunitiesThe three executive objections every product manager must answer: unique pain solved, economic switching benefit, and beachhead proofKeywords: life science marketing, conference preparation, battle cards, AI-assisted prep, TAM analysis, market sizing, pain point differentiation, beachhead strategy, portfolio review, ELRIG survey, competitive intelligence, customer discoverySubscribe to Strivenn Thinking for weekly insights on AI-enabled life science marketing. Visit strivenn.com for frameworks, tools, and strategic resources.

Brand investment rises while performance tactics get commoditised - but will marketing teams shift budget or stick to old metrics?*Shownotes:*Strategic intent and operational reality diverge. Roxana's challenge cuts through the optimism: "We've tried everything, and then AI came, and everything seems to be for naught." That's not burnout, that's crisis.This episode is for life science marketing and sales leaders navigating the gap between what researchers say should happen and what actually gets budget approval. Matt and Jasmine unpack insights from a 60-minute RISE community session where seven marketers spoke with uncomfortable honesty about brand versus performance, AI's commoditisation of tactics, and the discipline required to prove brand value by January 2027. The core truth: predictions rarely survive first contact with the budget game.*What you will learn:** Why 70% of B2B buying ends with no decision and what role brand plays in unblocking those stalled deals* How CFOs now control 20% of six-figure deals while marketers measure MQLs that don't matter* The hidden cost of "secret cyborgs" using AI without governance in regulated life science environments* Why referred leads convert faster than any marketing qualified lead you'll ever generate* How to execute a dignified product end-of-life that protects customer relationships and frees engineering capacity* The two-axis framework (profitability vs strategic value) for triaging which products to sunset and which to extend*Chapters:*[0:00] Strivenn LLC announcement - North American expansion[1:39] Roxana's challenge: "We've tried everything, then AI came"[4:04] Why marketers ruin everything (and how AI accelerates it)[6:18] The expensive truth about measuring brand perception[8:26] Persuasion marketing and connecting dots to the sales funnel[9:56] Brand as the hub: word of mouth, persuasion, and trust[11:11] The most important lead is the one who was referred to you[12:28] Japanese market observations: size creates selling constraints[13:49] CFO involvement and the ROI pressure on marketing[15:03] Model Context Protocol (MCP) and e-commerce integration[16:28] Roxana's January 2027 deadline - strategic intent vs operational reality[18:00] Product end-of-life: when products reach the end of utility[21:14] The triage framework: profitability vs strategic value[24:41] Dignified exits: protocol conversion guides and transition pricing[28:09] Product inheritance: what declining products carry forward[30:02] Product end-of-life's knock-on effect on brand marketing*Subscribe and connect:*If this conversation helped you see the gap between strategic intent and what actually gets funded, subscribe to _A Splice of Life Science Marketing_ on https://youtube.com/@strivenn, https://open.spotify.com/show/your-show, or https://podcasts.apple.com/podcast/your-podcast. Visit http://strivenn.com for more insights on turning science into demand.

AI makes scaling easy - the winners use it to do better, not just more, by keeping human judgment in the loop.Shownotes:Most life science teams are stuck talking about AI transformation while competitors execute it. The gap between 68% AI optimism and 7% power users isn't about awareness - it's about execution.This episode is for biotech marketers and product managers navigating AI adoption and product development decisions. Matt and Jasmine explore why organisations retire risk by standardising rather than solving creatively - a pattern that undermines both AI implementation and product differentiation. The key insight: AI makes it dangerously easy to produce more without asking if the strategy underneath is broken. The winners use AI to do better, not just more.What you will learn:Why "secret cyborgs" using free AI tools with zero guardrails are a symptom of execution failureHow to move personas from static PDFs to interactive synthetic customers you can queryWhen to pause AI implementation because you're optimising the wrong workWhy Stage Gate committees systematically prune differentiation before launchHow product managers can defend customer pain points with veto authorityThe connection between AI pilot mode and launching commoditised productsKeywords: AI implementation life science, synthetic customer persona, AI execution gap, Stage Gate product development, biotech marketing strategy, AI guardrails, product differentiation, crossing the chasm life science, voice of customer, AI literacyWatch the full episode, subscribe for weekly insights, and visit strivenn.com for tools to close your own execution gaps.

Your buyer has already decided before they ever speak with you. The question isn't whether you can persuade them—it's whether you've made it easy for them to justify choosing you.This episode is for life science product managers and marketers in biotech, medtech, and diagnostics who want to close the gap between what customers say and what they actually do. Matt and Jasmine unpack the uncomfortable truth about where purchase decisions really happen, why field intelligence beats advisory boards, and what survivability signaling means for vendor selection in 2026.What you will learn:Why buyers build mental shortlists long before filling in contact formsHow to audit content for quotability, not just persuasivenessWhat fragility signals accidentally broadcast vendor instabilityWhy product managers must spend time in the field (and what to capture)How ethnographic observation reveals pain that surveys consistently missWhy messaging must evolve through the product adoption curveChapters: [00:03] Introduction [01:46] Article 1: The execution gap in life science marketing [03:48] Where decisions actually happen (before contact) [06:43] Survivability signaling and fragility signals [13:18] Article 2: Field intelligence and product management [16:21] Why specificity matters more than reach [21:18] Spending time in the field transforms requirements [25:39] Ethnographic research vs theoretical voice of customer [28:17] Post-launch observation sharpens messaging [31:25] Closing thoughts

AI can scale research, but delegating presence has hidden costs. Life science marketers face six seismic shifts in 2026 that demand human judgement.This episode is for marketing and product managers in biotech, medtech and diagnostics navigating the tension between AI efficiency and strategic presence. Matt and Jasmine unpack when AI accelerates discovery and when showing up yourself is the only option that builds conviction, captures contradictions and earns trust.What you will learn:The PHASE framework to decide when you must be present in customer discovery versus when AI can handle itWhy cognitive offloading erodes your ability to defend strategic pivots with convictionSix converging trends from Forrester, McKinsey, Gartner and IDC reshaping life science marketing in 2026How AI is changing discovery processes and why account-level metrics now matter more than lead volumeThe shift from the golden age of digital marketing to what Jasmine calls the "platinum age" of hyper-personalizationWhy human connection at events and in field application conversations remains irreplaceableChapters:[00:00] Welcome and Season Two introduction[02:44] The Janus threshold explained: when to delegate presence to AI[06:56] The PHASE framework: Purpose, Hypothesis, Action, Solutions, Endorsement[11:07] Being present to check AI summaries and build relationships[13:24] Six major shifts hitting life science marketers in 2026[16:53] From golden age to platinum age: staying human while using AI[19:53] One opportunity to focus on in 2026Subscribe to A Splice of Life Science Marketing for sharp strategic conversations every week. Visit strivenn.com for frameworks, tools and insights that help you earn trust and stand out.

Most buyer personas end up in a drawer. You spent weeks on workshops, interviews, and research - then created a pretty PDF that nobody opens again. What if that document could talk back?In this episode of Splice of Life Science Marketing, Jasmine Gruia-Gray interviews Matt Wilkinson about PersonaAI - a process that transforms traditional persona documents into interactive synthetic customers powered by AI. This isn't about replacing human insight. It's about making that insight usable every single day.Who this is for: Life science marketers, product managers, and commercial teams who want their buyer research to actually work for them - not gather dust.The key idea: Static persona documents become powerful strategic tools when converted into AI-powered synthetic customers you can query, challenge, and create with.What you will learn:Why traditional personas fail after the initial project endsHow to build synthetic customers using LinkedIn profiles and AI reasoning modelsPractical applications: website reviews, sales pitch rehearsal, content creation, and product developmentHow Matt used PersonaAI to prep for a keynote and received harder questions from the AI than from the live audienceThe role of voice-of-customer data in enriching your synthetic personasHow to personalise ABM campaigns without being creepy

You're spending tens of thousands on conference booths to acquire new customers. But are you actually ready to win them?Matt Wilkinson and Jasmine Gruia-Gray of Strivenn surveyed 107 exhibitors at ELRIG Drug Discovery 2025 and discovered a disturbing pattern: companies are acquisition-focused yet preparation-poor. While 61% struggle with lead quality, only 14% have competitive battle cards ready. Worse still, most exhibitors couldn't articulate what makes them memorable, had no strategic conversation frameworks, and were improvising competitor responses on the fly.This isn't about budget constraints—it's about strategic negligence. Companies are treating conferences as lead-scanning exercises rather than architecting experiences that convert prospects into pipeline. The "rinse and repeat" approach is failing, and hope is not a commercial plan.What you will learn:Why acquisition focus without preparation creates a dangerous disconnectThe preparation trifecta missing from most booths: battle cards, memorable messaging, strategic follow-upHow to use the STAR model to handle competitor questions with confidence instead of improvisationWhy marketers must be at conferences to capture intelligence that drives future positioningPre-show targeting tactics that book meetings with your exact ICP before the show floor opensHow Atlas and persona AI transform conference prep from guesswork to strategic role-playingKeywords:life science marketing, conference strategy, ELRIG Drug Discovery, competitive preparation, battle cards, memorable differentiation, strategic booth conversations, acquisition strategy, life science tools, trade show ROI, conference planning, customer acquisitionReady to stop wasting your conference investment? Preparation determines whether you're memorable or invisible among 200 booths. Subscribe for more unvarnished life science marketing insights, and visit strivenn.com to access our AI Readiness Diagnostic.

Having AI tools doesn't mean your organisation is using them effectively - 38% of employees are experimenting with AI personally, becoming 'secret cyborgs' without guidance or guardrails.Your team is using AI right now. The question is: with or without you?In this episode of A Splice of Life Science Marketing, Matt Wilkinson and Jasmine Gruia-Gray unpack findings from their ELRIG Drug Discovery 2025 survey of 107 life science exhibitors. The data reveals a troubling pattern: organisations are buying AI tools, but adoption remains fragmented, unguided, and risky. Most concerning? 38% of employees in organisations without AI programmes are already experimenting personally - becoming what Ethan Mollick calls "secret cyborgs."This conversation challenges the assumption that access equals adoption. It explores why light users hold the key to AI growth, how the Dunning-Kruger effect shapes power user confidence, and why software-as-a-service companies are outpacing traditional life science vendors in AI maturity.What you'll learn:Why 44% of survey respondents have tried AI but aren't using it daily - and what that means for commercial teamsThe "secret cyborg" phenomenon: how employees are adopting AI without organisational guidance or guardrailsWhy AI readiness matters more than budget - and how structured programmes drive 53-73% daily usage ratesThe cognitive offloading risk: what happens when we stop challenging AI outputs and exercising our mental musclesHow SaaS companies achieved higher AI maturity than tools, reagents, and automation providersPractical steps to close the confidence gap between light users and power users through AI clubs and train-the-trainer modelsChapters:0:04 - Introduction and survey context1:30 - The light user paradox: gym memberships vs AI adoption3:27 - Are power users overestimating readiness? The Dunning-Kruger effect5:31 - Cautious optimism: what 68% of respondents really feel about AI8:52 - Cognitive offloading: the hidden risk of AI dependency11:03 - Why correlation isn't causation in AI-assisted analysis12:58 - SaaS companies and AI maturity: why they're ahead15:00 - The secret cyborg problem: 38% are experimenting without guidance18:17 - Beyond text generation: where AI sophistication breaks down21:15 - Closing the confidence gap: AI clubs and collaborative learning24:34 - AI maturity as competitive differentiator: WPP vs Publicis27:26 - Creating space for human connection in an AI-augmented worldKeywords: AI adoption, life science marketing, secret cyborgs, AI readiness, ELRIG survey, cognitive offloading, AI maturity, light users, power users, AI governance, commercial teams, life science vendorsSubscribe to A Splice of Life Science Marketing for more insights on marketing strategy, AI adoption, and commercial growth in the life sciences. Visit strivenn.com to explore our AI readiness diagnostic and persona development tools.

Your antibody copy could land you an FDA warning letter. One wrong phrase on your website transforms a research tool into an unapproved diagnostic device in the eyes of regulators.This conversation is for marketing managers at life science tools companies who need to promote Research Use Only (RUO) products without crossing regulatory lines. Josh Levin, former FDA compliance officer and diagnostics consultant, explains exactly which words trigger investigations and how to communicate analytical performance without implying diagnostic intent. Words matter: phrases like "used in diagnosis" or "detects disease" create regulatory risk; safer language references literature findings or analytical capabilities.What you will learn:The specific RUO disclaimer language FDA requires and where it must appearRed flag phrases that imply diagnostic claims versus safe alternatives that reference published researchWhy written website copy receives more FDA scrutiny than verbal sales conversationsHow to present clinical data and analytical performance without crossing into diagnostic territoryWhat compliance language belongs in distributor agreements to prevent off-label promotionThree strategic tips for tools companies considering entry into the diagnostic spaceChapters:[0:00] Introduction and defining Research Use Only[1:26] What RUO means and how FDA determines intended use[2:29] Required RUO statement placement and formatting[3:58] What manufacturers can and cannot say about RUO products[6:35] Red flag words versus safe phrasing for website copy[9:23] Framing analytical data without implying clinical validity[12:01] Application notes and case study guardrails[13:09] How AI might change FDA compliance monitoring[14:24] Working with diagnostic and clinical lab customers[21:38] Distributor compliance and partner training[22:51] Combined-function instruments and software considerations[26:13] Three tips for tools companies entering diagnosticsKeywords: Research Use Only, RUO products, FDA compliance, life science marketing, diagnostic claims, regulatory copywriting, antibody marketing, lab developed tests, ISO 13485, clinical lab regulations, tools manufacturer compliance, FDA warning lettersReady to ensure your marketing copy stays compliant? Watch this essential conversation, subscribe for more regulatory insights, and visit strivenn.com for expert guidance on life science marketing strategy.

Joeri Billast reveals how CMOs become Chief Value Officers by speaking CFO language, building trust, and orchestrating impact across teams.CMOs today face an impossible balancing act: prove ROI to finance while staying credible with technical audiences. Joeri Billast, author of The Future CMO (endorsed by Philip Kotler), joins Matt and Jasmine to reveal how marketing leaders can bridge both worlds.This episode is for life science marketers who need to demonstrate value, build trust through data, and lead transformation without controlling every function. Joeri shares practical frameworks from 250+ executive conversations on his Web3 CMO Stories podcast.The Future CMO is here today, and everyone should read it.What you will learn:How to speak CFO language and prove marketing's financial impactWhy trust is the currency that defines modern CMOsHow to balance scientific credibility with business outcomesThe three-pillar value dashboard: perception, trust, and outcomeSmall actions early-career marketers can take to build executive credibilityHow AI helps CMOs spot patterns and early signals across customer touchpointsChapters:[00:01] Introduction and celebrating the book launch[01:38] The one-sentence pitch for The Future CMO[03:14] What Philip Kotler's endorsement means[05:31] The aha moment that sparked the book[07:56] Speaking CFO language while staying credible with scientists[13:48] Trust as the defining currency for CMOs[17:29] AI's role in the future of marketing leadership[29:44] Leading transformation as an early-career marketer[33:16] CMOs as Chief Value Officers orchestrating distributed teamsKeywords: life science marketing, CMO leadership, marketing ROI, CFO language, trust building, AI in marketing, organizational transformation, value creation, Philip Kotler, Web3 CMOReady to future-proof your marketing leadership? Watch the full conversation, subscribe for more life science marketing insights, and visit strivenn.com for tools and resources.

If you think performance marketing is the whole game, you’re leaving money on the table. This conversation shows why brand is the force-multiplier that makes performance work.For biotech startup marketers, we define “performance branding,” show how to measure it across the buyer journey, and share scrappy plays to build trust, loyalty, and revenue—because branding eats performance for breakfast.Who it’s for: Biotech startup marketers, life science PMMs, founders wearing the marketing hat.What we cover:What “performance branding” really means (it’s brand, tied directly to revenue, win rate, margins, LTV—not fluffy veneer)Why scientists aren’t “immune to brand” (trust, community, credible support)How to measure memory + money (share of search, branded search, repeat traffic, win rates, price realization, pipeline velocity)Human-centric buyer journeys in an AI era (omnichannel webs, consistent claims + proof)Consistency as competitive advantage (repeat the strongest claim, then repeat it again)Shoestring plays for scrappy teams (one killer app note, head-to-head data, meet personas where they are)Where AI helps (deep research, RAG, prompt libraries) without going roboticKEY IDEA: Branding eats performance for breakfast.What you will learn:How to define performance branding and align it to revenue, win rate, and LTVA practical metric stack that blends memory (brand) and money (business outcomes)How to design consistent claims + proof points scientists actually trustA lightweight plan to pilot performance branding on a small budgetWhere to use AI for research and content without losing authenticityHow to build community and advocacy to accelerate pipeline velocityChapters:[00:02] Sponsor + intro[00:48] Why performance branding now[01:58] Definition: brand tied to business outcomes[03:46] Aggregating across channels, not single-touch[04:32] Search behavior & brand recognition in B2B[06:12] Are scientists immune to branding? (No.)[11:19] Measuring memory + money[14:21] Human-centric buyer journey (AI era)[16:34] Consistent claims → competitive advantage[20:00] Misconceptions early marketers inherit[23:19] Shoestring performance branding for startups[27:04] Using AI without losing your soul[32:45] Prompt libraries & marketer “style” models[37:13] Planning season: make room for performance brandingKeywords:performance branding, biotech marketing, life science marketing, brand vs performance, buyer journey, pipeline velocity, share of search, AI in marketing, scientific marketing, B2B branding, Oxford Nanopore, NEBWatch the full episode, hit subscribe for more actionable life science marketing plays, and visit www.strivenn.com for templates and tools to put performance branding to work.